NASDAQ$CGEM
Cullinan Oncology Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Cullinan Oncology reported financial results for the fourth quarter and full year 2023 and provided a corporate update.
Cullinan Oncology reported a net loss of $25.6 million for the fourth quarter of 2023, with cash, cash equivalents, investments, and interest receivable totaling $468.3 million as of December 31, 2023. The company's cash resources are expected to provide runway into the second half of 2026. They also remain on track to report additional solid tumor dose escalation data for CLN-619 in Q2 2024 and received FDA clearance for an IND to evaluate CLN-619 in relapsed/refractory multiple myeloma.
- Cash and investments totaled $468.3 million as of December 31, 2023, providing runway into the second half of 2026.
- R&D expenses were $34.8 million for the fourth quarter of 2023.
- G&A expenses were $10.6 million for the fourth quarter of 2023.
- Net loss for the fourth quarter of 2023 was $25.6 million.
Headline financials
Revenue & EPS history
Cullinan Oncology · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
+0.5%
Avg return
Earnings day
-0.2%
Avg return
5 days after
-2.1%
Avg return
30 days after
55%
11 / 20 earnings
Positive
+13.5%
Q1 2022
Best reaction
-10.8%
Q2 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -2.6% | +7.7% | -10.0% | |
| Q3 2025 | +0.8% | +6.7% | +44.9% | |
| Q2 2025 | -10.8% | -7.7% | -11.3% | |
| Q1 2025 | +2.3% | +1.3% | +5.8% | |
| Q4 2024 | +1.9% | -3.8% | -5.1% | |
| Q3 2024 | -2.8% | -2.8% | -20.8% | |
| Q1 2024 | -9.7% | -9.1% | -28.4% | |
| Q4 2023 | -6.2% | -8.7% | -1.8% | |
| Q3 2023 | -2.7% | -11.1% | -17.7% | |
| Q2 2023 | +4.3% | -1.4% | -0.6% | |
| Q1 2023 | +1.2% | -5.3% | +36.0% | |
| Q4 2022 | -1.5% | +3.3% | -9.1% | |
| Q3 2022 | +3.8% | +1.0% | -3.0% | |
| Q2 2022 | -5.6% | +0.8% | -3.5% | |
| Q1 2022 | +13.5% | +6.8% | +12.1% | |
| Q4 2021 | +8.8% | +3.0% | -8.6% | |
| Q3 2021 | -4.5% | -10.1% | -28.8% | |
| Q2 2021 | +7.8% | +3.8% | +8.0% | |
| Q1 2021 | +2.2% | +12.4% | +13.1% | |
| Q4 2020 | +9.5% | +8.4% | -13.9% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro